Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Bromfenac ophthalmic - InSite Vision

Next Previous
Drug Profile

Bromfenac ophthalmic - InSite Vision

Alternative Names: Bromfenac ophthalmic 0.075%; BromSite; ISV-101; ISV-303

Latest Information Update: 08 Sep 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator InSite Vision; Sun Pharmaceutical Industries
  • Class Analgesics; Benzophenones; Bromobenzenes; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular inflammation; Ocular pain
  • No development reported Dry eyes; Retinal oedema

Most Recent Events

  • 08 Sep 2021 No development reported - Phase-I/II for Dry eyes in USA (Ophthalmic)
  • 28 Aug 2018 No recent reports of development identified for research development in Retinal oedema(Prevention) in USA (Ophthalmic, Drops)
  • 08 Sep 2017 InSite Vision plans a phase II trial of bromfenac ophthalmic for Dry eye disease in 2018 (NCT01478555)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top